At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality: ? Testing and validating our foundational scientific perspective ? Redefining manufacturing ? Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform:?https://bit.ly/39dHRwm
Carisma Therapeutics
生物技术研究
Philadelphia，Pennsylvania 15,288 位关注者
Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors
关于我们
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.
- 网站
-
https://carismatx.com
Carisma Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Philadelphia，Pennsylvania
- 类型
- 上市公司
- 创立
- 2016
地点
-
主要
获取路线
3675 Market St, Ste 401
US，Pennsylvania，Philadelphia，19104
Carisma Therapeutics员工
-
Richard Morris
Chief Financial Officer at Carisma Therapeutics
-
Daniel Blumenthal
Director of Preclinical Development | Biotech Leader | Preclinical Drug Development | IND Strategy | LNP/mRNA & Cell Therapy | Translational Research
-
Nancy Leigh Carson
Histologist at Carisma Therapeutics
-
John Hohneker
Independent Board Member, Consultant, and Advisor
动态
-
Join Michael Klichinsky, Co-Founder and Chief Scientific Officer of Carisma Therapeutics, as he gives an update on CAR-M and engineered myeloid cell strategies at the Keystone Symposia on Molecular & Cellular Biology – Immune Cell Therapies: Advances in Cancer and Autoimmune Disease on March 19th in the Plenary Session (Alternative Immune Effectors) at 10 AM ET, virtually and in Banff. Link: https://lnkd.in/eTAvU_2Q
-
Michael Klichinsky PhD, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, will be presenting an update on myeloid cell therapy for solid tumors at the Society for Immunotherapy of Cancer (SITC) Spring Scientific Meeting. Stay tuned for updates!
The Spring Scientific, Cellular Therapy for Solid Tumors, is almost here! This year's program will take place in San Diego, CA & Virtually from March 12–14, 2025. #SITC will bring the brightest minds and the next generation of leaders together to explore the more promising science and develop novel opportunities to address these challenges. Invited Faculty Speakers: Christine Brown, PhD, Jennifer Guerriero, PhD, John Haanen, MD, PhD, Christopher A. Klebanoff, M.D., Daniel Powell, Jr., PhD, Evan Weber, PhD, Renier Brentjens, MD, PhD, Katie Campbell, PhD, Julia Carnevale, MD, Jeffrey Chou, MD PhD, George Coukos, MD, PhD, Justin Eyquem, Joseph Fraietta, PhD, Luca Gattinoni, MD, Stephen Gottschalk, MD, James R. Heath, PhD, Michael Klichinsky, PhD, Sri Krishna, PhD, Jason Luke, MD, FACP, Crystal Mackall, MD, FAIO, Robert Manguso, PhD, Gordon Moody, MS, Hideho Okada, MD, PhD, Maria Parkhurst, PhD, Cristina Puig Saus, PhD, Rizwan Romee, MD, Kole Roybal, PhD, Wouter Scheper, PhD, Inge Marie Svane, MD, PhD, Jan ter Meulen, MD, PhD, Mark Yarmarkovich, PhD. To learn more about the Spring Scientific, visit: go.sitcancer.org/4fupoc0
-
-
Tune in today at 10:30 AM ET! Join Carisma's Co-founder and Chief Scientific Officer, Michael Klichinsky, PharmD, PhD, as he participates in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. Watch the webcast live via the Investor section of our website: https://bit.ly/3TvbKNh
-
-
Next week, we’re excited to participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. For full details and webcast information, check out our press release:?https://lnkd.in/e985cYxH
-
-
Exciting News! Our CT-0508 Phase 1 trial results are published today in Nature Medicine. This first-in-human CAR-Macrophage trial for heavily pre-treated metastatic HER2+ solid tumors validates the CAR-M mechanism, showing anti-tumor activity, TME remodeling, and induction of anti-tumor immunity along with a favorable safety profile. Building on this progress, we are advancing CT-1119, our next-gen anti-Mesothelin CAR-monocyte, into a Phase 1 trial for ovarian & pancreatic cancers this year, with data expected 4Q 2025. Check out the full publication below: https://lnkd.in/em3b9Ght
-
Our President and CEO, Steven Kelly, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 4:40 PM ET. Stay tuned for updates! For full details and webcast information, read our press release:?https://lnkd.in/eSnaUZEN #Healthcare #Biotech #Immunotherapy #OppenheimerConference
-
-
Pleased to announce the publication of our preclinical work in Nature Communications, showcasing the synergy between CAR-M and PD-1 blockade in solid tumors. Congratulations to lead author Stefano Pierini and the outstanding team at Carisma Therapeutics for their dedication and remarkable contributions to this achievement. Link: https://lnkd.in/eMyeiUcp #Immunotherapy #CARM #Innovation #CarismaTherapeutics
-
Don’t miss Carisma Therapeutics President & Chief Executive Officer Steven Kelly fireside chat today at the?7th Annual Evercore HealthCONx Conference at 9:35 am ET. The webcast is available on the investor section of our website: https://lnkd.in/eyHna8cV
-
-
Happy Thanksgiving from Carisma Therapeutics! This Thanksgiving, we extend our heartfelt gratitude to all who support and inspire our mission to transform immunotherapy. Your trust drives us to innovate and strive for meaningful change in healthcare. May your day be filled with warmth, happiness, and cherished moments with loved ones. Wishing you and your families a joyous and memorable Thanksgiving! #Thanksgiving #Gratitude #Innovation #CarismaTherapeutics
-